1. Home
  2. ETON vs KALV Comparison

ETON vs KALV Comparison

Compare ETON & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.71

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.91

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
KALV
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
551.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
KALV
Price
$16.71
$16.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$29.67
$26.43
AVG Volume (30 Days)
277.8K
1.6M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,316,000.00
$1,426,000.00
Revenue This Year
$113.27
N/A
Revenue Next Year
$36.70
$204.16
P/E Ratio
N/A
N/A
Revenue Growth
102.77
N/A
52 Week Low
$11.09
$7.30
52 Week High
$23.00
$17.28

Technical Indicators

Market Signals
Indicator
ETON
KALV
Relative Strength Index (RSI) 49.52 70.46
Support Level $16.13 $15.88
Resistance Level $17.05 $17.10
Average True Range (ATR) 0.76 1.08
MACD 0.16 0.22
Stochastic Oscillator 79.06 96.52

Price Performance

Historical Comparison
ETON
KALV

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: